A FTSE 100 super growth stock I’d spend £2,000 on today

This FTSE 100 (INDEXFTSE: UKX) stock is in great shape to keep doling out delicious earnings growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors sifting the FTSE 100 for super growth stocks can do a lot worse than to tap into NMC Health (LSE: NMC), in my opinion.

The company is a major provider of private healthcare in the United Arab Emirates, and has already seen earnings swell at a compound annual growth rate of 23% over the past half a decade. And City analysts are predicting that profits are about to pick up speed in 2018, a 45% advance currently being anticipated. An extra 23% advance is forecast for 2019.

Yet despite its proven growth credentials NMC Health can still be picked up for next to nothing. Look past a forward P/E ratio of 33.5 times and this becomes apparent, its corresponding PEG reading standing at a sub-1 reading of 0.7.

M&A mammoth

What’s more, NMC Health carries a bonus in that dividends are expected to keep growing at a stratospheric rate just like earnings. In 2018 the shareholder reward is expected to fly to 19p per share from 13p last year, and again to 24 cents in 2019. These projections yield 0.5% and 0.7% respectively.

It’s not difficult to see why the Square Mile is so bullish on the healthcare star’s profits outlook. A combination of rising population levels and personal incomes in its developing regions should lay the path for strong and sustained profits advances long into the future.

And NMC Health is investing heavily in its operations to capitalise on these fertile conditions. Thanks to a string of asset acquisitions in recent times, the number of hospital beds on its books doubled in 2017 to 1,365 from 679 a year earlier.

The acquisition hunt shows little sign of slowing. In February the Footsie firm boosted its footprint in Saudi Arabia by securing an 80% holding in the Al Salam Medical Group for an initial $37m, a deal that includes a 100-bed hospital as well as two medical centres. It also secured a 70% stake in cosmetics surgery specialist CosmeSurge for $170m.

Just RELX

Another FTSE 100 super growth stock worthy of your attention today is RELX (LSE: RELX).

Recent annual growth may not be as impressive as that of NMC Health, but the bottom line has still swelled by double-digit percentages over the past couple of years. And like the hospital provider, thanks to its decent revenues prospects on foreign shores, the Square Mile’s army of brokers is expecting earnings to continue stomping higher.

Rises of 4% and 5% are forecast for 2018 and 2019 respectively and this leads to predictions of meaty dividend growth as well — last year’s payment of 39.4p per share is expected to stride to 42.2p in the current period and to 44.8p in 2019. Yields stand at a meaty 2.8% for this year and 2.9% for next year as a consequence.

And solid market commentary released this week convince me that RELX should make good on these estimates. The information and analytics provider advised that it is confident it should “deliver another year of underlying growth in revenue and in adjusted operating profit.”

With the business also busy on the M&A front — it has made four acquisitions since the turn of 2018 for an aggregated £668m — the outlook is also bright here. I believe solid market conditions and exciting portfolio reshaping makes RELX worthy of a slightly-toppy forward P/E multiple of 18.1 times.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended RELX. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Here’s how someone could start investing in 2025 with just £1,000

Planning to start investing in 2025? This writer highlights two very different stocks that might be worth considering for a…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

I asked ChatGPT which UK stocks Warren Buffett might look to buy. It suggested these 5 names

ChatGPT has some ideas about FTSE 100 stocks Warren Buffett might have been buying. But Stephen Wright thinks a closer…

Read more »

Investing Articles

Up 14% today! Here’s one growth stock that Elon Musk likes

A UK growth stock has signed another contract with SpaceX. But does this mean it deserves a place in my…

Read more »

Investing Articles

I asked ChatGPT if the FTSE 100 would hit 10,000 this year. It’s feeling bullish!

The FTSE 100's flying and Harvey Jones is feeling bullish. His obvious next step was to ask a chatbot where…

Read more »

Investing Articles

Near 52-week lows, are these FTSE 100 stocks now unmissable bargains?

Two FTSE 100 titans just can't stop falling in value. Paul Summers looks at whether investors should see this as…

Read more »

Investing Articles

Bill Ackman just loaded up on this top stock for his FTSE 100-listed fund

The well-known hedge fund manager has announced a massive holding in this tech stock for his FTSE 100-listed investment trust.

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Billionaire Bill Ackman has just made a huge bet on this S&P 500 growth stock

Bill Ackman just bought 30m shares in this well-known S&P 500 company. He believes it’s currently trading well below its…

Read more »

Investing Articles

40 and no pension? Here’s what £400 a month in a Stocks and Shares ISA could become

It's never too late to start investing for retirement. Here's how regular contributions to a Stocks and Shares ISA could…

Read more »